ESMO 2024 | DESTINY-Breast15: anticipating the impact of HER2-low status

Giuseppe Viale • 15 Sep 2024

ESMO 2024

Giuseppe Viale, MD, FRCPath, University of Milan, Milan, Italy, highlights the potential of the DESTINY-Breast15 trial (NCT05950945) to expand treatment benefits for patients with HER2-low status. He notes the importance of including patients who lack HER2 immunoactivity, which could broaden the spectrum of those eligible for targeted therapies. This trial builds on the findings of the Phase III DESTINY-Breast06 trial (NCT04494425) and could lead to more inclusive treatment options for a wider patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.